Somayeh Vafaei^1,2*, Maryam Mansoori^1,2, Maryam Sahlolbei^1,2, Asiye Akbarian³, Fatemeh Aghaei⁴ and Zahra Madjd^1,2*

¹Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran
²Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
³Department of Immunology, Tarbiat Modares University, Tehran, Iran
⁴Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran

*Corresponding Author: Somayeh Vafaei, Department of Molecular Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.

Received: April 14, 2021; Published: September 06, 2021

Abstract

  December 2019 was the initiation of a major challenge for the global health community. World attention shifted to novel beta coronavirus disease 2019 (COVID-2019) that caused the severe acute respiratory syndrome. Commonly, infected droplets transmitted by inhalation among people lead to disease. Detection of the virus in respiratory secretions by special molecular tests and computerized tomographic chest scan is usually possible. The role of a wide range of therapeutic agents is investigated to help 2019-nCoV patients. Given the extensive research in this area, it is necessary to perform a literature to review the currently published paper results. We focused to gather related articles about the molecular pathology of 2019-nCoV. Based on our results, suggested that interferon pretreatment and immunomodulatory agents to decline the cytokine storm and can be helpful in fighting COVID-19, this is while that community-wide vaccination undoubtedly can develops immunity and definitely provides protection.

Keywords: Coronavirus; 2019-n-CoV; COVID-19; Molecular Pathology; Treatment; Vaccine

References

1. Cyranoski D. “Mystery deepens over animal source of coronavirus”. Nature 7797 (2020): 18-19.
2. Alberca GGF., et al. “Coronavirus disease-2019 and the intestinal tract: An overview”. World Journal of Gastroenterology 13 (2021): 1255-1266.
3. Betaenou S., et al. “Atypical Manifestations of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children: A Review”. Current Pediatric Reviews (2021).
4. Wang X., et al. “Challenges to the system of reserve medical supplies for public health emergencies: reflections on the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in China”. Bioscience in Trends1 (2020): 3-8.
5. Deng YY., et al. “Single-cell RNA sequencing data suggest a role for angiotensin-converting enzyme 2 in kidney impairment in patients infected with 2019-nCoV”. Chinese Medical Journal (Engl) 133.9 (2020): 1129-1131.
6. Corman VM., et al. “Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR”. Euro Surveillance: Bulletin Europeen sur les maladies transmissibles = European Communicable Disease Bulletin3 (2020).
7. Ravikanth R. “Diagnostic accuracy and false-positive rate of chest CT as compared to RT-PCR in coronavirus disease 2019 (COVID-19) pneumonia: A prospective cohort of 612 cases from India and review of literature”. The Indian Journal of Radiology and Imaging 31 (2021): S161-S169.
8. Li J-Y., et al. “The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future”. Microbes and Infection (2020).
9. Cyranoski D. “Did pangolins spread the China coronavirus to people?” Nature (2020).
10. Bai WZ., et al. “Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2”. Journal of Medical Virology (2020).
11. Benvenuto D., et al. “The 2019‐new coronavirus epidemic: Evidence for virus evolution”. Journal of Medical Virology4 (2020): 455-459.
12. Angeletti S and Benvenuto D. “COVID-2019: The role of the nsp2 and nsp3 in its pathogenesis” (2020).
13. Zeiss CJ., et al. “Animal Models of COVID-19. I. Comparative Virology and Disease Pathogenesis”. ILAR Journal 9 (2021).
14. Cheng J., et al. “The neuroinvasive potential of SARS-CoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients”. Journal of Medical Virology (2020).
15. Cong Y., et al. “Nucleocapsid Protein Recruitment to Replication-Transcription Complexes Plays a Crucial Role in Coronaviral Life Cycle”. Journal of Virology4 (2020): e01925-02019.
16. Chan JF., et al. “Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan”. Emerging Microbes and Infections1 (2020): 221-236.
17. Chan JFW., et al. “Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan”. Emerging Microbes and Amp; Infections1 (2020): 221-236.
18. Shen Z., et al. “Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients”. Influenza and Other Respiratory Viruses (2020).
19. Qin C., et al. “Dysregulation of immune response in patients with COVID-19 in Wuhan, China”. Clinical Infectious Diseases (2020).
20. Coutard B., et al. “The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade”. Antiviral Research 176 (2020).
21. Paraskevis D., et al. “Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event”. Infection, Genetics and Evolution (2020): 104212.
22. Wen F., et al. “Identification of the hyper-variable genomic hotspot for the novel coronavirus SARS-CoV-2”. The Journal of Infection6 (2020): 671-693.
23. Biswas N., et al. “Structural and Drug Screening Analysis of the Non-structural Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 Virus Extracted From Indian Coronavirus Disease 2019 Patients”. Frontiers in Genetics 12 (2021): 626642.
24. Chen Y., et al. “Structure analysis of the receptor binding of 2019-nCoV”. Biochemical and Biophysical Research Communications 1 (2020): 135-140.
25. Seyran M., et al. “The structural basis of accelerated host cell entry by SARS-CoV-2dagger”. The FEBS Journal (2020).
26. Phan LT., et al. “Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam”. New England Journal of Medicine9 (2020): 872-874.
27. Shanmugaraj B., et al. “Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)”. Asian Pacific Journal of Allergy and Immunology1 (2020)10-18.
28. Market M., et al. “Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies”. Frontiers in Immunology 11 (2020): 1512.
29. Morse JS., et al. “Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV”. ChemBioChem5 (2020): 730-738.
30. Liu Y., et al. “Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury”. Science China Life Sciences3 (2020): 364-374.
31. Zhang DH., et al. “In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus”. Journal of Integrative Medicine2 (2020): 152-158.
32. Habibzadeh P and Stoneman EK. “The Novel Coronavirus: A Bird's Eye View”. Journal of Medical Virology2 (2020): 65-71.
33. Richardson P., et al. “Baricitinib as potential treatment for 2019-nCoV acute respiratory disease”. The Lancet 10223 (2020): e30-e31.
34. Stebbing J., et al. “COVID-19: combining antiviral and anti-inflammatory treatments”. Lancet Infectious Disease 4 (2020): 400-402.
35. Russell B., et al. “Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence”. Ecancermedicalscience 14 (2020): 1022.
36. Tetro JA. “Is COVID-19 receiving ADE from other coronaviruses?” Microbes and Infection2 (2020): 72-73.
37. Chen L., et al. “Convalescent plasma as a potential therapy for COVID-19”. Lancet Infectious Disease4 (2020).
38. Name JJ., et al. “Zinc, Vitamin D and Vitamin C: Perspectives for COVID-19 With a Focus on Physical Tissue Barrier Integrity”. Frontiers in Nutrition 7 (2020): 606398.
39. Tabibi S., et al. “Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients”. Journal of Intensive Care Medicine9 (2020): 827-835.
40. Tian X., et al. “Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody”. Emerging Microbes and Infections 1 (2020): 382-385.
41. Persad G., et al. “Public Perspectives on COVID-19 Vaccine Prioritization”. JAMA Network Open4 (2021): e217943.
42. Society of Pediatrics CMA, Editorial Board CJoP. “Recommendations for the diagnosis, prevention and control of the 2019 novel coronavirus infection in children (first interim edition)”. Zhonghua Er Ke Za Zhi 58 (2020): E004-E.
43. Han Q., et al. “Recent insights into 2019-nCoV: a brief but comprehensive review”. The Journal of Infection 4 (2020).
44. Guzzi PH., et al. “Master Regulator Analysis of the SARS-CoV-2/Human Interactome”. Pathogens 4 (2020).
45. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. The Lancet10223 (2020): 497-506.

Citation

Citation: Somayeh Vafaei., et al. “Molecular Characterization 2019 Novel Coronavirus (COVID-19): A Review of the Current Literature”.Acta Scientific Medical Sciences 5.10 (2021): 11-19.

Copyright

Copyright: © 2021 Somayeh Vafaei., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.